Pharmacodynamic and Pharmacokinetic Profile of a Novel GLP-1 Receptor Biased Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was developed.

WuXi AppTec recently contributed to a study which characterized the pharmacodynamic and pharmacokinetic profile of SAL0112.  The findings in this work suggest that SAL0112 exhibits effectiveness comparable to danuglipron and liraglutide in a rodent type 2 diabetes and obesity model and has the potential to offer an improved pharmacokinetic profile in the clinic.